Potentiation of cisplatin activity by the bioreductive agent tirapazamine

Radiotherapy and Oncology

Volumn 47, Issue 2, 1998, Pages 215-220

  Siemann, Dietmar W ^a   Hinchman, Cheri A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

16C mammary carcinoma; Chemopotentiation; Cisplatin; Tirapazamine

Indexed keywords

CISPLATIN; TIRAPAZAMINE; UREA;

ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; TRIAZINES;

EID: 0031829934     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)00224-7     Document Type: Article

References (24)

1. Adams, G.E. Hypoxic cell sensitizers for radio-therapy. In: Cancer, A Comprehensive Treatise, Vol. 6, pp. 181-224. Editor: F.F. Beck. Plenum Press, New York, 1977.
2. Adams, G.E., Ahmed, I., Sheldon, P.W. and Stratford, I.J. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br. J. Cancer 49: 571-577, 1984.
3. Adams, G.E. and Stratford, I.J. Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. Biochem. Pharmacol. 35: 71-76, 1986.
4. Brown, J.M. Tirapazamine: a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67: 1163-1170, 1993.
5. Corbett, T.H., Griswald, D.P., Jr., Roberts, B.J., Peckham, J.C. and Schabel, F.M., Jr. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat. Rep. 62: 1471-1488, 1978.
6. Dorie, M.J. and Brown, J.M. Tumor-specific, schedule dependent interaction of tirapazamine (SR 4233) and cisplatin. Cancer Res. 53: 4633-4636, 1993.
7. Dorie, M.J. and Brown, J.M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic agent tirapazamine. Cancer Chemother. Pharmacol. 39: 361-366, 1997.
8. Holden, S.A., Teicher, B.A., Ara, G., Herman, T.S. and Coleman, C.N. Enhancement of alkylating agent activity by SR-4233 in the FsaIIC murine fibrosarcoma. J. Natl. Cancer Inst. 84: 187-193, 1992.
9. Jenkins, T.C., Naylor, M.A., O'Neill, P., Threadgill, M.D., Cole, S., Stratford, I.J., Adams, G.E., Fielden, E.M., Suto, M.J. and Stier, M.A. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem. 33: 2603-2610, 1990.
10. Langmuir, V.K., Rooker, H.A., Osen, M., Mendonca, H.L. and Laderoute, K.R. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res. 54: 2845-2847, 1994.
11. Lartigau, E. and Guichard, M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br. J. Cancer 73: 1480-1485, 1996.
12. Lee, F.Y.F. and Workman, P. Modification of CCNU pharmacokinetics by misonidazole - a major mechanism for chemosensitization in mice. Br. J. Cancer 47: 659-669, 1983.
13. Mulcahy, R.T. Update: the potential for chemosensitization of alkylating agents by nitroimidazoles. Oncology 2: 17-27, 1988.
14. Noether, J. Introduction To Statistics - A Fresh Approach. Houghton Mifflin, Boston, MA, 1971.
15. Siemann, D.W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys. 10: 1585-1594, 1984.
16. Siemann, D.W. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother. Oncol. 34: 47-53, 1995.
17. Siemann, D.W. The in situ tumor response to combinations of cyclophosphamide and tirapazamine. Br. J. Cancer 74: 65-69, 1996.
18. Siemann, D.W. and Allalunis-Turner, M.J. Potentiation of combination chemotherapy by nitroheterocyclics. Int. J. Radiat. Oncol. Biol. Phys. 15: 129-134, 1988.
19. Siemann, D.W., Maddison, K. and Wolf, K. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069. Int. J. Radiat. Oncol. Biol. Phys. 10: 1657-1660, 1984.
20. Siemann, D.W. and Mulcahy, R.T. Sensitization of cancer chemotherapeutic agents by nitroheterocyclics. Biochem. Pharmacol. 35: 111-115, 1986.
21. Siemann, D.W. and Sutherland, R.M. In vivo tumor response to single and multiple exposures of adriamycin. Eur. J. Cancer 16: 1433-1440, 1980.
22. Treat, J., Haynes, B., Johnson, E., Belani, C., Greenberg, R., Rodriquez, R., Drobbins, P., Miller, W., Jr., Meehan, L. and von Roemeling, R. Tirapazamine with cisplatin: a phase II trial in advanced stage non-small cell lung cancer (NSCLC) (abstract). Proc. ASCO 16: 455, 1997.
23. Zeman, E.M., Hirst, V.K., Lemmon, M.J. and Brown, J.M. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR4233. Radiother. Oncol. 12: 209-218, 1988.
24. Zeman, E.M., Brown, J.M., Lemmon, M.J., Hirst, V.K. and Lee, W.W. SR 4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12: 1239-1242, 1986.